Diabetes clinical trials at UC Irvine

8 in progress, 5 open to eligible people

Showing trials for

  • Conscious Pregnancy: Supporting Maternal Cardiometabolic Health With Mindfulness

    open to eligible females ages 18 years and up

    A pilot randomized control trial (RCT) to examine the efficacy of a culturally tailored mindfulness intervention upon fasting cardiometabolic factors (including markers of glycemic control) and inflammatory gene expression in n=60 (n=30 intervention, n=30 wait-list control) low-income Spanish-speaking Latina pregnant women. The study will be conducted in partnership with MOMS, a nonprofit community organization that serves low-income pregnant and postpartum women.

    Santa Ana 5392900, California 5332921

  • Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial

    open to eligible people ages 18-99

    This randomized controlled trial will investigate whether use of continuous glucose monitoring (CGM) vs. usual care with self-monitored blood glucose 1) enhances glycemic control, 2) reduces hypoglycemia risk, and 3) improves quality of life, diabetes distress, and fear of hypoglycemia in hemodialysis patients with diabetes mellitus.

    Orange 5379513, California 5332921

  • Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

    open to eligible people ages 18-99

    The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

    Orange 5379513, California 5332921 and other locations

  • HOPE Intervention for Fitness

    open to eligible people ages 18 years and up

    We will test the HOPE intervention on changing behavior of people to exercise more (take more steps each day).

    Irvine 5359777, California 5332921

  • RAY121 in Immunological Diseases (RAINBOW Trial)

    open to eligible people ages 18-85

    This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

    Orange 5379513, California 5332921 and other locations

  • Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

    Sorry, accepting new patients by invitation only

    In this pilot clinical trial, the investigators will recruit and randomize 120 patients with diabetes mellitus and chronic kidney disease (CKD/DM) stages 3 to 5 to a patient-centered and flexible Plant-Focused Nutrition in Diabetes (PLAFOND) diet with >2/3 plant-based sources, which will be compared with a standard-of-care CKD diet, which is usually a low-potassium and low-salt diet, over a 6-month period. Through this study, the investigators will determine whether the plant-focused diet intervention is feasible for patient adherence, whether this diet is safe by avoiding malnutrition, frailty, and high potassium or glucose blood levels, and whether patient reported outcomes are favorably impacted.

    Orange 5379513, California 5332921 and other locations

  • AT-001 in Patients With Diabetic Cardiomyopathy

    Sorry, in progress, not accepting new patients

    This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.

    Orange 5379513, California 5332921 and other locations

  • Continuation of the nuMoM2b Heart Health Study

    Sorry, accepting new patients by invitation only

    Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in U.S. women at all ages, and large knowledge gaps exist in CVD predictive and preventative strategies for women. The nuMoM2b Heart Health Study (nuMoM2b-HHS) has followed a demographically diverse cohort of women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospectively collected for up to 7 years thereafter. The overarching scientific goal of this study is to define the relationship between adverse pregnancy outcomes (APOs) and CVD to optimize CVD prediction, prevention, and treatment strategies for women. Continued follow-up of this observational cohort, building on a foundation of existing high-quality data, biospecimens, and administrative structures with a robust framework for ancillary study development and implementation, provides a unique opportunity to address knowledge gaps regarding the early mechanisms and trajectory of CVD in women.

    Orange 5379513, California 5332921 and other locations

Our lead scientists for Diabetes research studies include .

Last updated: